Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Melanoma
  • Unresectable or Metastatic Melanoma

NCT number NCT01844505
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Active, not recruiting
Phase Phase 3
Start date June 11, 2013
Completion date October 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06359860 - A Study of ST-1898 for Unresectable or Metastatic Melanoma Phase 1/Phase 2
Terminated NCT03993379 - PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors Phase 2
Terminated NCT01810016 - NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Phase 1
Active, not recruiting NCT05783882 - Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma Phase 3
Completed NCT01721746 - A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) Phase 3
Recruiting NCT04674683 - Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma Phase 3